What is SkyCell?
Founded in 2012 and headquartered in Zug, Switzerland, SkyCell specializes in the manufacturing of high-performance, temperature-controlled containers designed to ensure the integrity of pharmaceutical products during transit. The company operates at the nexus of life sciences and logistics, providing critical infrastructure that mitigates the risks associated with global cold chain distribution. By leveraging proprietary technology and data-driven monitoring, SkyCell enables pharmaceutical manufacturers to maintain product efficacy while navigating complex international regulatory environments. Their market position is defined by a commitment to sustainability and reliability, serving as a vital partner for global healthcare organizations that require precision in their supply chain management.
How much funding has SkyCell raised?
SkyCell has raised a total of $269.8M across 4 funding rounds:
Other Financing Round
$62M
Series C
$34.8M
Other Financing Round
$57M
Series D
$116M
Other Financing Round (2020): $62M with participation from BCGE Bank, Swiss Entrepreneurs Fund, and MVM Partners
Series C (2021): $34.8M, investors not publicly disclosed
Other Financing Round (2023): $57M supported by Catalyst
Series D (2024): $116M featuring Catalyst Investors, Tybourne Capital Management, and Commonwealth Cyber Initiative
Key Investors in SkyCell
Catalyst Investors
Catalyst Investors is a growth equity firm located in New York that specializes in actively helping B2B companies scale their operations and achieve their full potential.
Tybourne Capital Management
Tybourne Capital Management is an investment advisory firm that offers a variety of investment related services to clients.
Commonwealth Cyber Initiative
The Commonwealth Cyber Initiative serves as a hub for cybersecurity research, innovation, and workforce development, connecting researchers with strategic funding opportunities.
What's next for SkyCell?
With the successful closure of this latest financing round, SkyCell is poised to accelerate its strategic initiatives, focusing on the expansion of its global service network and the integration of next-generation IoT monitoring capabilities. The company is expected to leverage this capital to enhance its manufacturing capacity, meeting the rising demand for secure, compliant, and efficient pharmaceutical transport solutions. As the industry faces increasing pressure to optimize logistics for sensitive biologics and vaccines, SkyCell's focus on technological innovation and operational excellence will likely remain the primary driver of its long-term value creation and market leadership.
See full SkyCell company page
